Engineering predictive tissue models
The field of tissue engineering and regen erative medicine has seen tremendous prog ress over the past few decades through a wide spectrum of engineering innovations in biomaterials, biomolecule delivery, bio mechanics, biophysics and biomedicine. For example, scaffolds are fabricated to possess controllable structures, porosities, hierarchies, degradability along with well controlled spatial and temporal presentation of bioactive molecules (e.g., growth factors, antagonists, DNAs and micro/siRNAs) that aid in regulating cellular behavior [1] . Moreover, it is increasingly appreciated that biomechanical cues of the materials can be employed to direct the differentiation of stem cells into specific lineages [2] . Alterna tively, cellular behaviors may also be tuned by other biophysical cues including surface roughness and topography [3] .
However, since its conception, tissue engi neering has always focused on the generation of tissue substitutes to replace those damaged or diseased in the body. Only recently has the area started to enter an emerging paradigm of building physiologically relevant minia ture human tissue and organ models. The increasing awareness in animal welfare has further expedited such efforts in generating human tissue models that may eventually replace animal models from the ethical per spective as well as to provide more accurate predictions of human body responses.
Indeed, there have been tremendous progress on developing functional human healthy/diseased organoids from vari ous human cell sources including induced pluripotent stem cells (iPSCs), genetically modified cell lines and diseased cells derived from patients. For example, Helmrath and colleagues showed that through iPSC dif ferentiation and subsequent maturation by transplanting under the kidney capsules of immunocompromised mice, human small intestinal organoids could form that contain mature intestinal epithelium with cryptvillus architecture and a laminated mesenchyme [4] . Also, Knoblich and colleagues demonstrated the potential to generate human brain regions that recapitulated the structure and develop ment of cerebral cortex in 3D iPSCderived cerebral organoids [5] . In another example, Kim and colleagues created a model of famil ial Alzheimer's disease (FAD) using a 3D cul ture system of differentiated neuronal cells expressing FAD mutations, which expressed amyloidβ and phosphorylated tau proteins, similar to those of FAD in human brains [6] . While these examples are still preliminary, the findings have undoubtedly provided sig nificant excitement about generating predic tive human tissue models for drug testing. More interestingly, realistic human tumor Seeking the right context for evaluating nanomedicine: from tissue models in petri dishes to microfluidic organs-on-a-chip future science group Editorial Zhang & Khademhosseini models have also been engineered that represent the tumor characteristics in vivo. In a pioneering example, Mooney and colleagues created a 3D model of human oral cancer by culturing oral squamous cell carcinoma cells within highly porous scaffolds prepared from the synthetic biomaterial poly(lactidecoglycolide), which showed similar levels of biomarker secretion with in vivo tumor models, significantly higher than those observed in 2D monolayer cultures [7] .
A critical limitation in fabricating functional tis sue models lies in the inability to drive the cells under in vitro cultures to form hierarchical, ordered struc tures that recapitulate those found in human body. Although it is demonstrated that via rational design of the matrices certain cell populations can sort them selves into simplified biomimetic structures due to the differential mechanics and membrane properties of the cells [8] , such capability is rather limited. To address this challenge, advancements have been made in vari ous biofabrication techniques such as 3D bioprinting. Bioprinting holds great potential to surpass the obsta cles associated with generating biomimetic tissue archi tecture by controlling the spatial fabrication of biologi cal architectures, including both cells and extracellular matrix molecules, in a scalable manner [9] . We envision that, with further development of the 3D bioprinting technology, it will be possible to produce tissue and organ models that mimic many aspects of their human counterparts. As an example, biomimetic blood vessels with interconnected lumen structures and a tight layer of endothelium have been fabricated via a sacrificial approach following digitized bioprinting of template materials [10, 11] . Besides hollow vascular structures cre ated by sacrificial printing, other tissuelike structures such as skin, bone, airway, heart and cartilage have also been directly bioprinted [9] . It is not unreasonable to assume that these advanced bioprinting techniques can be readily applied to the creation of complex tumor tis sues possessing the right cellular/matrix structures and architecture.
Connecting them together: building the human-on-a-chip platform
In human body tissues and organs of all types are inter connected by a sophisticated network of blood vessels. The vascular network enables the communication among different organs, via the transport of biochemi cal cues and circulating cells. This circulatory system is critically important in allowing for selfcontainment of the human body by coordinating the functions of different organs at distance. In such an integrated envi ronment neither organs nor their responses are isolated, meaning that the behavior of one organ upon treat ment of a substance (e.g., drug) will usually trigger a cascade of reactions of other organs that otherwise do not respond to the molecule by themselves alone. Therefore, in building realistic in vitro tissue models it is significant to implement a microfluidic platform where multiple bioreactors housing different organ models are introduced into the same context where the crosstalk among these organs take place, the socalled 'organsonachip' systems [12] [13] [14] [15] [16] [17] [18] [19] [20] . Such models can be made across a range of complexity from either individ ual or multiple organ types. For example, Takayama and colleagues generated microfluidic airway systems that could be used for studying cellularlevel lung inju ries [21] . Also, Ingber and colleagues have generated several organ models on chips including lung, kidney, blood vessel, airway and bone marrow [22] . In addition, Shuler and colleagues piloted the micro cell culture analog devices where up to ten organs including tumor units are integrated in order to study their interactions [23] . Similarly, Wikswo and colleagues proposed the microphysiological systems with builtin pneumatic valves to control the 'blood flow' among different organs [24] . Many other collaborative efforts around the world including our own group are at the same time pioneering advanced integration technologies that can advance these biomimetic modules toward the final aim of constructing a viable 'humanonachip' platform.
In order to run a platform with multiple organ types, a common medium, typically referred to as blood surrogate, must be developed to maintain the viability and functionality of all the organs. The scal ing effect, defined as the compositional, architectural and functional outcomes of change in size among simi larly organized animals, is another major consideration in engineering the organsonachip platforms. In fact with the variation in organ/body size of vertebrate ani mal species spanning across a huge range on the mag nitude of 10 6 , the scaling of parameters such as organ weight, metabolism and blood volume/flow obey dif ferent laws. It has been suggested that appropriate scal ing laws should be adopted for specific applications depending on whether it is to engineer physiologically functional multipleorgan systems (e.g., beating heart onachip), pharmacological models of organ interac tions, or both [15] . However, we believe that a universal scaling effect may be derived to eventually miniaturize the human physiology onto microfluidic chips that fit for different applications.
" In order to run a platform with multiple organ types, a common medium, typically referred to as blood surrogate, must be developed to maintain the viability and functionality of all the organs. "
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Better models for evaluating nanomedicine The field of nanomedicine has made critical advance ments to enable the fabrication of various nanoma terials with different properties that can be used as vehicles for sustained, stimuliresponsive, as well as targeted delivery of therapeutic drugs and diagnostic agents [25] . Tremendous efforts in studying the effi ciency and efficacy of nanomedicine have largely relied on 2D cell culture models, but in most cases the results obtained from these studies do not readily translate to in vivo scenarios due to the fundamental difference of these oversimplified models comparing with native tissues and organs. For example, cellular uptake and cytotoxicity of nanoparticles in 2D setups are far more efficient and higher than when they are administrated to 3D models that recapitulate the density of native tissues in human body to a much stronger degree than 2D monolayers. Using these 3D tissue/tumor models, the delivery of nanoparticles with different param eters such as size, shape, surface charge and configura tions have been investigated [26] . Although improved, these dense 3D constructs may only provide insights on diffusionmediated drug delivery resembling the stage where the nanoparticles have exited from the blood vessels to reach the interstitial space of the tis sues. Therefore, the need to introduce a physiologi cally relevant microfluidic vasculature into the tumor model seems critical in studying the systemic effects of nanomedicine, which has triggered boosted interest in engineering tumoronachip platforms [27, 28] . Further combination with healthy organs in the circulation not only provides the capability to assess the thera peutic effects of nanomedicine toward tumors but also reveals its systemic side effects on other healthy organs reachable by the blood flow.
Conclusion
There is a strong demand in engineering in vitro tis sue models that accurately recapitulate the biology and physiology of organs in the human body for evalua tion of nanomedicine to promote the wellbeing of human life. Through the merger of tissue engineer ing technologies with individualspecific human cells, human organ (tumor) models can be fabricated that better mimic human physiology or pathology. By fur ther integrating proper blood surrogate and scaling laws, such 'humanonachip' systems have potential to function as a robust platform that both applies to fundamental studies of biological agents and diseases, as well as to predicting the effects of nanomedicine in humans.
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